InterPAD - DETAILS

glipizide, 29094-61-9, Glucotrol, Glydiazinamide, Dipazide, Glibenese, Glucozide, Glupizide, Melizide, Minodiab, Napizide, Sucrazide, Mindiab, Glucotrol XL, Glibetin, Glidiab, Glucolip, Glupitel, Minidab, Minidiab, Aldiab, Digrin, Glican, Glipid, Glyde, Ozidia, Gluco-Rite, Glipizidum, Glipizida, Glipizidum [INN-Latin], Glipizida [INN-Spanish], K 4024, N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-5-methylpyrazine-2-carboxamide, CP 28720, CP-28720, K-4024, TK 1320, CP 28,720, Glipizide slow release, CP-28,720, UNII-X7WDT95N5C, EINECS 249-427-6, X7WDT95N5C, MFCD00072159, 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea, NSC-759120, BRN 0903495, CHEBI:5384, DTXSID0040676, N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide, Glidiazinamide, Glypidizine, Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-, Glide, CHEMBL1073, MLS000069386, N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea, CP 28720;K 4024, DTXCID8020676, Glipizide [USAN:USP:INN:BAN], METAGLIP COMPONENT GLIPIZIDE, Urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)-, N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide, N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide, NSC 759120, NCGC00015462-07, SMR000058455, Glipizidum (INN-Latin), CAS-29094-61-9, Glipizida (INN-Spanish), GLIPIZIDE (MART.), GLIPIZIDE [MART.], 1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea, 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea, GLIPIZIDE (USP-RS), GLIPIZIDE [USP-RS], GLIPIZIDE (EP MONOGRAPH), GLIPIZIDE [EP MONOGRAPH], GLIPIZIDE (USP MONOGRAPH), GLIPIZIDE [USP MONOGRAPH], Glipizide (USAN:USP:INN:BAN), 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea, N-{4-[beta-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea, Glucotrol (TN), Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-, Glipizide (USP/INN), SR-01000000010, Glipizideer, GlipizideXL, GlucotrolXL, GlipizideERER, Glipizide ER, Glipizide XL, Glipizide, solid, N-(2-(4-((cyclohexylcarbamoyl)sulfamoyl)phenyl)ethyl)-5-methylpyrazine-2-carboxamide, N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-5-methylpyrazine-2-carboxamide, N-[4-[N-(Cyclohexylcarbamoyl)sulfamoyl]phenethyl]-5-methylpyrazine-2-carboxamide, glipizide/glucotrol, Glipizide,(S), N-[2-[4[[[(Cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide; 1-Cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido), Prestwick_242, KS-1068, Metaglip (Salt/Mix), Glipizide (Glucotrol), GLIPIZIDE [INN], GLIPIZIDE [JAN], GLIPIZIDE [MI], Lopac-G-117, GLIPIZIDE [USAN], Opera_ID_1908, Prestwick0_000131, Prestwick1_000131, Prestwick2_000131, Prestwick3_000131, GLIPIZIDE [VANDF], G-117, GLIPIZIDE [WHO-DD], CBiol_001788, Lopac0_000621, SCHEMBL17094, BSPBio_000202, BSPBio_001349, KBioGR_000069, KBioSS_000069, MLS001148176, BIDD:GT0476, SPBio_002141, BPBio1_000224, GTPL6821, GLIPIZIDE [ORANGE BOOK], KBio2_000069, KBio2_002637, KBio2_005205, KBio3_000137, KBio3_000138, Bio1_000074, Bio1_000563, Bio1_001052, Bio2_000069, Bio2_000549, GLXC-20257, HMS1361D11, HMS1568K04, HMS1791D11, HMS1989D11, HMS2089C21, HMS2093J09, HMS2095K04, HMS2233N11, HMS3259K12, HMS3261N04, HMS3369L12, HMS3402D11, HMS3655G04, HMS3712K04, Pharmakon1600-01505433, BCP09195, HY-B0254, Tox21_110156, Tox21_301834, Tox21_500621, BBL028143, BDBM50012956, NSC759120, NSC813218, s1715, STK631952, AKOS005564405, GLIPIZIDE COMPONENT OF METAGLIP, N-[4-(3-Cyclohexylureidosulfonyl)phenethyl]-5-methyl-2-pyrazinecarboxamide, Tox21_110156_1, CCG-204710, DB01067, LP00621, NC00564, NSC-813218, SDCCGSBI-0050603.P003, IDI1_033819, Glipizide 100 microg/mL in Acetonitrile, NCGC00015462-01, NCGC00015462-02, NCGC00015462-03, NCGC00015462-04, NCGC00015462-05, NCGC00015462-06, NCGC00015462-08, NCGC00015462-09, NCGC00015462-10, NCGC00015462-11, NCGC00015462-12, NCGC00015462-14, NCGC00015462-23, NCGC00016802-01, NCGC00023748-03, NCGC00023748-04, NCGC00023748-05, NCGC00023748-06, NCGC00023748-07, NCGC00255522-01, NCGC00261306-01, 2-Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-, AC-15789, SY009252, SBI-0050603.P002, EU-0100621, FT-0626714, FT-0659737, G0369, NS00009815, SW196549-3, D00335, Q3108899, SR-01000000010-2, SR-01000000010-5, W-107005, BRD-K12219985-001-04-8, BRD-K12219985-001-15-4, Z1575081877, Glipizide, European Pharmacopoeia (EP) Reference Standard, Glipizide, United States Pharmacopeia (USP) Reference Standard, Glipizide, Pharmaceutical Secondary Standard; Certified Reference Material, 1-cyclohexyl-3-(4-(2-(2-methylpyrazine-5-carboxamido)ethyl)phenylsulfonyl)urea, 1-Cyclohexyl-3-{{p=[2-[5-methylpyrazine-carboxamido)-ethyl]phenyl}sulphonyl}urea, N-(4-(.beta.-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea, 172964-66-8, N-(2-[4-(([(Cyclohexylamino)carbonyl]amino)sulfonyl)phenyl]ethyl)-5-methyl-2-pyrazinecarboxamide

Name	Glipizide
PubChem CID	3478
Molecular Weight	445.5g/mol
Synonyms	glipizide, 29094-61-9, Glucotrol, Glydiazinamide, Dipazide, Glibenese, Glucozide, Glupizide, Melizide, Minodiab, Napizide, Sucrazide, Mindiab, Glucotrol XL, Glibetin, Glidiab, Glucolip, Glupitel, Minidab, Minidiab, Aldiab, Digrin, Glican, Glipid, Glyde, Ozidia, Gluco-Rite, Glipizidum, Glipizida, Glipizidum [INN-Latin], Glipizida [INN-Spanish], K 4024, N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-5-methylpyrazine-2-carboxamide, CP 28720, CP-28720, K-4024, TK 1320, CP 28,720, Glipizide slow release, CP-28,720, UNII-X7WDT95N5C, EINECS 249-427-6, X7WDT95N5C, MFCD00072159, 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea, NSC-759120, BRN 0903495, CHEBI:5384, DTXSID0040676, N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide, Glidiazinamide, Glypidizine, Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-, Glide, CHEMBL1073, MLS000069386, N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea, CP 28720;K 4024, DTXCID8020676, Glipizide [USAN:USP:INN:BAN], METAGLIP COMPONENT GLIPIZIDE, Urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)-, N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide, N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide, NSC 759120, NCGC00015462-07, SMR000058455, Glipizidum (INN-Latin), CAS-29094-61-9, Glipizida (INN-Spanish), GLIPIZIDE (MART.), GLIPIZIDE [MART.], 1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea, 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea, GLIPIZIDE (USP-RS), GLIPIZIDE [USP-RS], GLIPIZIDE (EP MONOGRAPH), GLIPIZIDE [EP MONOGRAPH], GLIPIZIDE (USP MONOGRAPH), GLIPIZIDE [USP MONOGRAPH], Glipizide (USAN:USP:INN:BAN), 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea, N-{4-[beta-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea, Glucotrol (TN), Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-, Glipizide (USP/INN), SR-01000000010, Glipizideer, GlipizideXL, GlucotrolXL, GlipizideERER, Glipizide ER, Glipizide XL, Glipizide, solid, N-(2-(4-((cyclohexylcarbamoyl)sulfamoyl)phenyl)ethyl)-5-methylpyrazine-2-carboxamide, N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-5-methylpyrazine-2-carboxamide, N-[4-[N-(Cyclohexylcarbamoyl)sulfamoyl]phenethyl]-5-methylpyrazine-2-carboxamide, glipizide/glucotrol, Glipizide,(S), N-[2-[4[[[(Cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide; 1-Cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido), Prestwick_242, KS-1068, Metaglip (Salt/Mix), Glipizide (Glucotrol), GLIPIZIDE [INN], GLIPIZIDE [JAN], GLIPIZIDE [MI], Lopac-G-117, GLIPIZIDE [USAN], Opera_ID_1908, Prestwick0_000131, Prestwick1_000131, Prestwick2_000131, Prestwick3_000131, GLIPIZIDE [VANDF], G-117, GLIPIZIDE [WHO-DD], CBiol_001788, Lopac0_000621, SCHEMBL17094, BSPBio_000202, BSPBio_001349, KBioGR_000069, KBioSS_000069, MLS001148176, BIDD:GT0476, SPBio_002141, BPBio1_000224, GTPL6821, GLIPIZIDE [ORANGE BOOK], KBio2_000069, KBio2_002637, KBio2_005205, KBio3_000137, KBio3_000138, Bio1_000074, Bio1_000563, Bio1_001052, Bio2_000069, Bio2_000549, GLXC-20257, HMS1361D11, HMS1568K04, HMS1791D11, HMS1989D11, HMS2089C21, HMS2093J09, HMS2095K04, HMS2233N11, HMS3259K12, HMS3261N04, HMS3369L12, HMS3402D11, HMS3655G04, HMS3712K04, Pharmakon1600-01505433, BCP09195, HY-B0254, Tox21_110156, Tox21_301834, Tox21_500621, BBL028143, BDBM50012956, NSC759120, NSC813218, s1715, STK631952, AKOS005564405, GLIPIZIDE COMPONENT OF METAGLIP, N-[4-(3-Cyclohexylureidosulfonyl)phenethyl]-5-methyl-2-pyrazinecarboxamide, Tox21_110156_1, CCG-204710, DB01067, LP00621, NC00564, NSC-813218, SDCCGSBI-0050603.P003, IDI1_033819, Glipizide 100 microg/mL in Acetonitrile, NCGC00015462-01, NCGC00015462-02, NCGC00015462-03, NCGC00015462-04, NCGC00015462-05, NCGC00015462-06, NCGC00015462-08, NCGC00015462-09, NCGC00015462-10, NCGC00015462-11, NCGC00015462-12, NCGC00015462-14, NCGC00015462-23, NCGC00016802-01, NCGC00023748-03, NCGC00023748-04, NCGC00023748-05, NCGC00023748-06, NCGC00023748-07, NCGC00255522-01, NCGC00261306-01, 2-Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-, AC-15789, SY009252, SBI-0050603.P002, EU-0100621, FT-0626714, FT-0659737, G0369, NS00009815, SW196549-3, D00335, Q3108899, SR-01000000010-2, SR-01000000010-5, W-107005, BRD-K12219985-001-04-8, BRD-K12219985-001-15-4, Z1575081877, Glipizide, European Pharmacopoeia (EP) Reference Standard, Glipizide, United States Pharmacopeia (USP) Reference Standard, Glipizide, Pharmaceutical Secondary Standard; Certified Reference Material, 1-cyclohexyl-3-(4-(2-(2-methylpyrazine-5-carboxamido)ethyl)phenylsulfonyl)urea, 1-Cyclohexyl-3-{{p=[2-[5-methylpyrazine-carboxamido)-ethyl]phenyl}sulphonyl}urea, N-(4-(.beta.-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea, 172964-66-8, N-(2-[4-(([(Cyclohexylamino)carbonyl]amino)sulfonyl)phenyl]ethyl)-5-methyl-2-pyrazinecarboxamide
Drug Type	Small molecule
Formula	C₂₁H₂₇N₅O₄S
SMILES	CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
InChI	1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
InChIKey	ZJJXGWJIGJFDTL-UHFFFAOYSA-N
CAS Number	29094-61-9
ChEMBL ID	CHEMBL1073
ChEBI ID	CHEBI:5384
TTD ID	D0Z4SB
Drug Bank ID	DB01067
KEGG ID	D00335
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Glipizide
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.